| Sun Pharmaceutical Industries Limited | Demerger | Interalia, to consider the proposal for demerger of the Company's Innovative Research and Development (including new drug delivery systems) undertaking to a new company. | 09-Feb-2006 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2010. (2) To consider recommendation of payment of dividend on equity shares for the year ended March 31, 2010 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 24-May-2010 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Inter alia (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2011. (2) To consider the recommendation of payment of Dividend on equity shares for the year ended March 31, 2011 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 28-May-2011 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2012; (2) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting. | 29-May-2012 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | The Company had informed the Exchange regarding a Board meeting to be held on August 10, 2012 interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2012. The Company has now informed the Exchange that Board meeting to be held on August 10, 2012 to consider the quarterly unaudited results of the Company interalia, the following additional agenda items also would be considered : (i) To consider the internal restructuring of the business of the Company with effect from March 31,2012. (ii) To consider declaration of the interim dividend of Rs.4.25 per Share of Re.1 each on Equity Shares of the Company for the year ended March 31, 2012 in lieu of the earlier recommended proposed dividend of Rs.4.25 per Share of Re.1 each on Equity Shares of the Company for the year ended March 31, 2012 in view of the likely delay for the redrawing and audit of the revised accounts for the year ended March 31, 2012 and adoption of accounts by the members due to the proposed restructuring of the business of the Company with effect from March 31,2012, if the Board approves the proposed restructuring. (Purpose Revised) | 10-Aug-2012 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record un-audited financial results of the Company for the third quarter ended December 31, 2012. | 08-Feb-2013 |
| Sun Pharmaceutical Industries Limited | Results | Inter-alia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2012. | 08-Feb-2013 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2013; (2) To consider the recommendation of payment of dividend for the year ended March 31, 2013, subject to the approval of the shareholders at the ensuing Annual General Meeting. | 28-May-2013 |
| Sun Pharmaceutical Industries Limited | Scheme of Arrangement | The Company has informed that the Hon'ble High Court of Gujarat, at Ahmedabad and Hon'ble High Court of Mumbai, at their respective hearing held both on May 03, 2013 approved the Scheme of Arrangement between Sun Pharmaceutical Industries Limited (SPIL) and Sun Pharma Laboratories Limited (SPLL) in the nature of Spin-Off and transfer of Domestic Formulation Business/Undertaking of SPIL to SPLL with effect from the appointed date of March 31, 2012. Further, the Company has informed that the certified copies of the High Court orders will be filed with the Registrar of Companies shortly as required and the spin off process would get completed. Further, in view thereof, the Board of Directors of the Company would also consider the revised audited annual accounts of the Company for the year ended March 31, 2012 after giving the effect to the above mentioned Scheme of Arrangement between SPIL and SPLL (along with the consideration of audited annual accounts of the Company for the year ended March 31, 2013) at their meeting to be held on May 28, 2013. | 28-May-2013 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2013 | 09-Aug-2013 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2013. | 13-Nov-2013 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2013. | 13-Feb-2014 |
| Sun Pharmaceutical Industries Limited | Results/Others | inter alia, to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2014. The said audited results are subject to revision so as to give effect of demerger with effect from May 01, 2013 of the Specified Undertaking of Sun Pharma Global FZE, the Company's wholly owned subsidiary company with the Company, after receipt of all required approvals from the statutory authorities in respect of the demerger. Further, note that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from May 20, 2014 to June 02, 2014 (both days inclusive). | 29-May-2014 |
| Sun Pharmaceutical Industries Limited | Results/Others | Inter alia, to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2014. The said audited results are subject to revision so as to give effect of demerger with effect from May 01, 2013 of the Specified Undertaking of Sun Pharma Global FZE, the Company's wholly owned subsidiary company with the Company, after receipt of all required approvals from the statutory authorities in respect of the demerger. Further, note that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from May 20, 2014 to June 02, 2014 (both days inclusive). | 29-May-2014 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | The Board of Directors of the Company would meet on August 12, 2014 to transact, inter alia, the following business. (i) Consider the revised audited annual accounts of the Company for the year ended March 31, 2014 after giving the effect to the above mentioned Scheme of Arrangement and Reconstruction between SPIL and SPGFZE. (ii) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2014 subject to the approval of the shareholders at the ensuing Annual General Meeting. (iii) To consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2014 (Q1). The window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from August 01, 2014 to August 14, 2014 (both days inclusive). | 12-Aug-2014 |
| Sun Pharmaceutical Industries Limited | Results | inter alia, to consider and take on record the un-audited financial results of the Company for the second quarter ended September 30, 2014. | 13-Nov-2014 |
| Sun Pharmaceutical Industries Limited | Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014. | 14-Feb-2015 |
| Sun Pharmaceutical Industries Limited | Results/Others | Interalia to consider and approve the audited financial results of the Company stand alone and consolidated for the year ended March 31, 2015. The said audited results are subject to revision so as to give effect of amalgamation of Sun Pharma Global Inc, our wholly owned subsidiary company, with the Company with effect from January 1, 2015, after receipt of all required approvals from the statutory authorities in respect of the amalgamation. | 29-May-2015 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Sun Pharmaceuticals Industries Limited had informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 11, 2015, Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015.The Company has now informed the Exchange that the Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 30, 2015 has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company, into Sun Pharmaceutical Industries Limited (SPIL) with effect from the appointed date of January 1, 2015. This is to further inform you that the certified copy of the High Court order is expected to be received shortly and will be filed with the Registrar of Companies there after as required and the process of merger would get completed on such filing.The Board of Directors of the Company at its meeting scheduled to be held on August 11, 2015 would also transact the following business:(i) Consideration of the revised audited annual accounts of the Company for the year ended 31st March, 2015 after giving the effect to the above mentioned Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend.(ii) Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 11-Aug-2015 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015. | 11-Aug-2015 |
| Sun Pharmaceutical Industries Limited | Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2015. | 07-Nov-2015 |
| Sun Pharmaceutical Industries Limited | Results/Others | interalia, to consider and take on record the Unaudited Financial Results of the Company for the Third quarter and nine months ended December 31, 2015. | 12-Feb-2016 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | interalia, to transact the following business :(i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the year ended March 31, 2016.(ii) To consider recommendation of dividend for the year ended March 31, 2016 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 30-May-2016 |
| Sun Pharmaceutical Industries Limited | Buyback | For evaluating a proposal of Buy Back of Equity Shares of the Company. | 23-Jun-2016 |
| Sun Pharmaceutical Industries Limited | Results | interalia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. | 12-Aug-2016 |
| Sun Pharmaceutical Industries Limited | Results/Others | To transact, interalia, the following business: a. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016.b. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. In view of the consideration of above items, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from November 1, 2016 to November 14, 2016 (both days inclusive). | 10-Nov-2016 |
| Sun Pharmaceutical Industries Limited | Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016. | 14-Feb-2017 |
| Sun Pharmaceutical Industries Limited | Results/Dividend | Interalia, to transact the following business : (i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. (ii) To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 26-May-2017 |
| Sun Pharmaceutical Industries Limited | Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. | 11-Aug-2017 |
| Sun Pharmaceutical Industries Limited | Results | to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. | 14-Nov-2017 |
| Sun Pharmaceutical Industries Limited | Results | To consider and take on record, the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. | 14-Feb-2018 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend | 25-May-2018 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 | 14-Aug-2018 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended September 30, 2018. Notice of Board Meeting for consideration and approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2018 and intimation of dates of Window Closure for Trading by Designated persons. | 13-Nov-2018 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended December 31, 2018 | 12-Feb-2019 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend | 28-May-2019 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 | 13-Aug-2019 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended September 30, 2019 | 07-Nov-2019 |
| Sun Pharmaceutical Industries Limited | Dividend | Consider declaration of Interim Dividend on the equity shares of the Company, for the Financial Year 2019-2020. | 06-Feb-2020 |
| Sun Pharmaceutical Industries Limited | Financial Results | To inter alia consider and approve the financial results for the period ended December 31, 2019 | 06-Feb-2020 |
| Sun Pharmaceutical Industries Limited | Buyback | To consider, inter alia, the proposal for buy-back of fully paid-up equity shares of the Company, which would include maximum amount, maximum number of equity shares, mode of buy-back and other matters incidental thereto in accordance with the provisions of Section 68, 69 and 70 of the Companies Act,2013, read with rules made thereto and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018.In this connection, as per the Company's code of conduct for prevention of insider trading, the trading window for dealing or trading in securities of the Company will remain closed with immediate effect for all directors, designated persons and insiders and shall re-open after the expiry of 48 hours after the conclusion of the aforesaid Board Meeting.proposal buyback for equity shares | 17-Mar-2020 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2020 and to consider recommendation of final dividend for the year ended March 31, 2020 subject to the approval of the shareholders at the ensuing Annual General Meeting. | 27-May-2020 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results financial results for the quarter ended Jun 30, 2020 | 31-Jul-2020 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2020 | 03-Nov-2020 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020 | 29-Jan-2021 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the audited financial results for the quarter and year ended March 31, 2021 and recommendation of final dividend for the year ended March 31, 2021. | 27-May-2021 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results for the quarter ended Jun 30, 2021 | 30-Jul-2021 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended September 30, 2021 | 02-Nov-2021 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended December 31, 2021 | 31-Jan-2022 |
| Sun Pharmaceutical Industries Limited | Financial results | Sun Pharmaceutical Industries Limited has informed the Exchange about Board Meeting to be held on 29-Jul-2022 to consider financial statements for the period ended June 2022 | 29-Jul-2022 |
| Sun Pharmaceutical Industries Limited | Financial results | Sun Pharmaceutical Industries Limited has informed the Exchange about Board Meeting to be held on 01-Nov-2022 to consider financial statements for the period ended September 2022 | 01-Nov-2022 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2022 and consider interim dividend | 31-Jan-2023 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend | 26-May-2023 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 | 03-Aug-2023 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended September 30, 2023 | 01-Nov-2023 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and interim dividend | 31-Jan-2024 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the audited financial results for the period ended March 31, 2024 and final dividend | 22-May-2024 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve Quarterly Financial Results for Q1 of FY 2024-25 | 01-Aug-2024 |
| Sun Pharmaceutical Industries Limited | Financial Results | To consider and approve the financial results for the period ended September 30, 2024 | 28-Oct-2024 |
| Sun Pharmaceutical Industries Limited | Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2024 and Interim dividend for FY 2024-25 | 31-Jan-2025 |
